Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome

Pediatric Neurology

Volumn 71, Issue , 2017, Pages 18-23.e2

  Kaplan, Emma H ^a   Offermann, Elizabeth A ^a   Sievers, Jacqueline W ^a   Comi, Anne M ^a,b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cannabidiol; intractable epilepsy; safety; Sturge Weber syndrome

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CANNABIDIOL; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; FELBAMATE; LACOSAMIDE; LAMOTRIGINE; LEVETIRACETAM; LORAZEPAM; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER; BRAIN; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DIVERGENT STRABISMUS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; STURGE WEBER SYNDROME; TREATMENT DURATION; YOUNG ADULT; COMPLICATION; TREATMENT OUTCOME;

ANTICONVULSANTS; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; DRUG RESISTANT EPILEPSY; FEMALE; HUMANS; MALE; QUALITY OF LIFE; SEIZURES; STURGE-WEBER SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85018672819     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2017.02.009     Document Type: Article

References (15)

1. Shirley, M.D., Tang, H., Gallione, C.J., et al. Sturge-Weber syndrome and port wine stains caused by somatic mutation in GNAQ. N Engl J Med 368 (2013), 1971–1979.
2. Comi, A.M., Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist 17 (2011), 179–184.
3. Comi, A.M., Current therapeutic options in Sturge-Weber syndrome. Semin Pediatr Neurol 22 (2015), 295–301.
4. Eivazi, B., Roessler, M., Pfützner, W., et al. Port-wine stains are more than skin-deep! Expanding the spectrum of extracutaneous manifestations of nevi flammei of the head and neck. Eur J Dermatol 22 (2012), 246–251.
5. Sullivan, T.J., Clarke, M.P., Morin, J.D., The ocular manifestations of the Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 29 (1992), 349–356.
6. Comati, A., Beck, H., Halliday, W., et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol 66 (2007), 86–97.
7. Alkonyi, B., Chugani, H.T., Karia, S., Behen, M.E., Juhász, C., Clinical outcomes in bilateral Sturge-Weber syndrome. Pediatr Neurol 44 (2011), 443–449.
8. Leo, A., Russo, E., Elia, M., Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol Res 107 (2016), 85–92.
9. Devinsky, O., Marsh, E., Friedman, D., et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15 (2016), 270–278.
10. England, T.J., Hind, W.H., Rasid, N.A., O'Sullivan, S.E., Cannabinoids in experimental stroke: a systematic review and meta-analysis. J Cereb Blood Flow Metab 35 (2015), 348–358.
11. Stanley, C.P., Hind, W.H., Tufarelli, C., O'Sullivan, S.E., Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res 107 (2015), 568–578.
12. O'Sullivan, S.E., Sun, Y., Bennett, A.J., Randall, M.D., Kendall, D.A., Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612 (2009), 61–68.
13. Kelley, T.M., Hatfield, L.A., Lin, D.D., et al. Quantitative analysis of cerebral cortical atrophy and correlation with clinical severity in unilateral Sturge-Weber syndrome. J Child Neurol 20 (2005), 867–870.
14. Bhattacharyya, S., Atakan, Z., Martin-Santos, R., et al. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Curr Pharm Des 18 (2012), 5045–5054.
15. Kluger, B., Triolo, P., Jones, W., et al. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30 (2015), 313–327.